文献速递白血病MDS 与骨髓增殖性肿瘤

慢性粒单核细胞白血病:2022年诊断、风险分层和管理更新

Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.
PubMed 文献 · Am J Hematol · 2022-01-27

本文综述慢性粒单核细胞白血病(CMML)的诊断、风险分层和管理更新。诊断基于持续超过3个月的外周血单核细胞增多(≥1×10^9/L;单核细胞≥10%),常伴骨髓发育异常。约30%患者有克隆性细胞遗传学异常,超过90%有体细胞基因突变。梅奥分子模型(MMM)将患者分为四组,中位生存期分别为16、31、59和97个月。低甲基化药物常用,总缓解率约40%-50%,完全缓解率约7%-17%。

要点

  • 诊断需持续超过3个月的外周血单核细胞增多(≥1×10^9/L;单核细胞≥10%),常伴骨髓发育异常。
  • 约30%患者有克隆性细胞遗传学异常,超过90%有体细胞基因突变。
  • MMM将患者分为高危(≥3个危险因素)、中危-2(2个)、中危-1(1个)和低危(无),中位生存期分别为16、31、59和97个月。

核心结论

  • CMML是一种克隆性造血干细胞疾病,兼具骨髓增生异常综合征和骨髓增殖性肿瘤特征,3-5年内白血病转化风险约15%。

研究设计与样本

  • 本文为综述,汇总CMML的诊断、风险分层和管理更新。

主要发现

  • 克隆性细胞遗传学异常见于约30%的患者,超过90%的患者有体细胞基因突变。
  • TET2(约60%)、SRSF2(约50%)、ASXL1(约40%)和致癌RAS通路(约30%)突变常见。
  • ASXL1和DNMT3A突变及TET2突变缺失对总生存有负面影响。
  • MMM的危险因素包括截短型ASXL1突变、绝对单核细胞计数>10×10^9/L、血红蛋白<10 g/dL、血小板计数<100×10^9/L和循环未成熟髓系细胞。
  • MMM将患者分为高危(≥3个危险因素)、中危-2(2个)、中危-1(1个)和低危(无),中位生存期分别为16、31、59和97个月。

关键数值与推荐

  • 诊断基于持续超过3个月的外周血单核细胞增多(≥1×10^9/L;单核细胞≥10%),常伴骨髓发育异常。

临床怎么用

  • 低甲基化药物如5-阿扎胞苷和地西他滨常用,总缓解率约40%-50%,完全缓解率约7%-17%,对突变等位基因负荷无影响。
  • 异基因干细胞移植是唯一可能治愈的选择,但与显著发病率和死亡率相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, with an inherent risk for leukemic transformation (~15% over 3-5 years). DIAGNOSIS: Diagnosis is based on the presence of sustained (>3 months) peripheral blood monocytosis (≥1 × 109 /L; monocytes ≥10%), usually with accompanying bone marrow dysplasia. Clonal cytogenetic abnormalities occur in ~30% of patients, while >90% have somatic gene mutations. Mutations involving TET2 (~60%), SRSF2 (~50%), ASXL1 (~40%), and the oncogenic RAS pathway (~30%) are frequent, while the presence of ASXL1 and DNMT3A mutations and the absence of TET2 mutations negatively impact overall survival. RISK-STRATIFICATION: Molecularly integrated prognostic models include the Groupe Français des Myélodysplasies, Mayo Molecular Model (MMM), and the CMML specific prognostic model. Risk factors incorporated into the MMM include presence of truncating ASXL1 mutations, absolute monocyte count >10 × 109 /L, hemoglobin <10 g/dL, platelet count <100 × 109 /L, and the presence of circulating immature myeloid cells. The MMM stratifies CMML patients into four groups: high (≥3 risk factors), intermediate-2 (2 risk factors), intermediate-1 (1 risk factor), and low (no risk factors), with median survivals of 16, 31, 59, and 97 months, respectively. RISK-ADAPTED THERAPY: Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of ~40%-50% and complete remission rates of ~7%-17%; with no impact on mutational allele burdens. Allogeneic stem cell transplant is the only potentially curative option but is associated with significant morbidity and mortality.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022. PMID: 34985762. doi:10.1002/ajh.26455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。